ObsEva SA (OBSV)

NASDAQ: OBSV · IEX Real-Time Price · USD
0.309
-0.031 (-9.12%)
At close: Aug 11, 2022 4:00 PM
0.315
+0.006 (1.909%)
Pre-market: Aug 12, 2022 7:50 AM EDT
-9.12%
Market Cap 25.86M
Revenue (ttm) n/a
Net Income (ttm) -50.17M
Shares Out 83.70M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,329,132
Open 0.332
Previous Close 0.340
Day's Range 0.286 - 0.332
52-Week Range 0.222 - 3.350
Beta 0.20
Analysts Buy
Price Target 6.43 (+1,980.9%)
Earnings Date Aug 8, 2022

About OBSV

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a recepto... [Read more...]

Industry Biotechnology
IPO Date Jan 26, 2017
CEO Ernest Loumaye
Employees 48
Stock Exchange NASDAQ
Ticker Symbol OBSV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for OBSV stock is "Buy." The 12-month stock price forecast is 6.43, which is an increase of 1,980.91% from the latest price.

Price Target
$6.43
(1,980.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy

ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces Management Change

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Why Is ObsEva (OBSV) Stock Down 70% Today?

Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.

ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment...

Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy

ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for t...

- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy -

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for...

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of...

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20 th Wo...

ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

GENEVA, Switzerland May 1 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment o...

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18,...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

7 Penny Stocks With 10x Potential This Year

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

Other symbols: FRSXIMPPKTRAMULNRGLS

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

-Linzagolix for uterine fibroids: Received c onfirmation of p ositive CHMP opinion for marketing authorization application ; United States NDA PDUFA date in Q3:22 -

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

GENEVA, Switzerland May 1 6 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company Mana...

What Are the Top 7 Penny Stocks? And Should You Buy?

Penny stocks carry considerable risk, but they can also generate life-changing returns. Here are some to consider buying today.

Other symbols: BGCPBTGSBTEFUWMC

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans t...

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 AC...

- Additional data from the PRIMROSE Phase 3 stud ies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15 am PT/12:15 pm ET-

ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of ...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Annual General Meeting 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Annual Report 2021

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg w...

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectivel...

ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update

-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion-

ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside ...